![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION
Canada Research Chair in Pharmacogenomics, Pharmacogenomics Laboratory, Oncology and Molecular Endocrinology Research Center, CHUL Research Center, Faculty of Pharmacy, Laval University, Québec, Canada
In vitro metabolic studies revealed that along with UDP-glucuronosyltransferase (UGT) 1A1, the hepatic UGT1A9 and the extrahepatic UGT1A7 are involved in the biotransformation of the active and toxic metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38). Variant UGT1A1 and UGT1A7 alleles have been reported but the polymorphic nature of the UGT1A9 gene has not been revealed yet. To further clarify the molecular determinants of irinotecan-induced toxicity, we have identified and characterized the functionality of novel UGT1A9 polymorphisms and determined whether additional missense polymorphisms exist in UGT1A7. Using direct DNA sequencing, four single nucleotide polymorphisms (SNPs) were identified in the first exons of UGT1A7 and UGT1A9. One of the two amino acid substitutions found in the UGT1A9 gene, UGT1A9*3 (M33T), results in a dramatic decrease in SN-38 glucuronide formation, with 3.8% of the activity of the UGT1A9*1 allele. In turn, the glucuronidation of flavopiridol, an anticancer drug biotransformed predominantly by UGT1A9, remains unaffected, indicating a substrate-dependent impact of this variant. UGT1A9*3 is detected only in Caucasians and 4.4% of the population tested was found heterozygous (*1/*3). Two additional UGT1A7 SNPs were found exclusively in African-American subjects and generate five alleles (UGT1A7*5 to *9) when combined to the four known SNPs present in UGT1A7*2, *3, and *4. Upon functional analysis with SN-38, five out of nine UGT1A7 allozymes exhibited much lower SN-38 glucuronidation activities compared with UGT1A7*1, all having in common the mutational changes at codons 115 or 208. Results suggest that these low SN-38 glucuronidating alleles may represent additional molecular determinants of irinotecan-induced toxicity and warrant further investigations.
Address correspondence to: Dr. Chantal Guillemette, Canada Research Chair in Pharmacogenomics, Oncology, and Molecular Endocrinology Research Center, CHUL Research Center (CHUQ), Faculty of Pharmacy, Laval University, Quebec G1V 4G2, Canada. E-mail: chantal.guillemette{at}crchul.ulaval.ca
This article has been cited by other articles:
|
|
 |
|
  M.-O. Benoit-Biancamano, J. Connelly, L. Villeneuve, P. Caron, and C. Guillemette Deferiprone Glucuronidation by Human Tissues and Recombinant UDP Glucuronosyltransferase 1A6: An in Vitro Investigation of Genetic and Splice Variants Drug Metab. Dispos., February 1, 2009; 37(2): 322 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Joy, M. La, and Bo Xiao Individualizing Therapy in Patients With Chronic Kidney Disease Journal of Pharmacy Practice, June 1, 2008; 21(3): 225 - 236. [Abstract] [PDF]
|
|
|
|
|
|
J. Ramirez, W. Liu, S. Mirkov, A. A. Desai, P. Chen, S. Das, F. Innocenti, and M. J. Ratain Lack of Association between Common Polymorphisms in UGT1A9 and Gene Expression and Activity Drug Metab. Dispos., December 1, 2007; 35(12): 2149 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Omura, T. Nakazawa, T. Sato, T. Iwanaga, and O. Nagata Characterization of N-Glucuronidation of 4-(5-Pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): A New Xanthine Oxidoreductase Inhibitor Drug Metab. Dispos., December 1, 2007; 35(12): 2143 - 2148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Bernard, J. Tojcic, K. Journault, L. Perusse, and C. Guillemette Influence of Nonsynonymous Polymorphisms of UGT1A8 and UGT2B7 Metabolizing Enzymes on the Formation of Phenolic and Acyl Glucuronides of Mycophenolic Acid Drug Metab. Dispos., September 1, 2006; 34(9): 1539 - 1545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Girard, L. Villeneuve, M. H. Court, L.-C. Fortier, P. Caron, Q. Hao, L. L. von Moltke, D. J. Greenblatt, and C. Guillemette THE NOVEL UGT1A9 INTRONIC I399 POLYMORPHISM APPEARS AS A PREDICTOR OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN GLUCURONIDATION LEVELS IN THE LIVER Drug Metab. Dispos., July 1, 2006; 34(7): 1220 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Han, H.-S. Lim, E. S. Shin, Y.-K. Yoo, Y. H. Park, J.-E. Lee, I.-J. Jang, D. Ho Lee, and J. Soo Lee Comprehensive Analysis of UGT1A Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non-Small-Cell Lung Cancer Treated With Irinotecan and Cisplatin J. Clin. Oncol., May 20, 2006; 24(15): 2237 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Gagnon, O. Bernard, L. Villeneuve, B. Tetu, and C. Guillemette Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer Clin. Cancer Res., March 15, 2006; 12(6): 1850 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chouinard, M. Tessier, G. Vernouillet, S. Gauthier, F. Labrie, O. Barbier, and A. Belanger Inactivation of the Pure Antiestrogen Fulvestrant and Other Synthetic Estrogen Molecules by UDP-Glucuronosyltransferase 1A Enzymes Expressed in Breast Tissue Mol. Pharmacol., March 1, 2006; 69(3): 908 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Kuehl, J. Bigler, J. D. Potter, and J. W. Lampe GLUCURONIDATION OF THE ASPIRIN METABOLITE SALICYLIC ACID BY EXPRESSED UDP-GLUCURONOSYLTRANSFERASES AND HUMAN LIVER MICROSOMES Drug Metab. Dispos., February 1, 2006; 34(2): 199 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Thibaudeau, J. Lepine, J. Tojcic, Y. Duguay, G. Pelletier, M. Plante, J. Brisson, B. Tetu, S. Jacob, L. Perusse, et al. Characterization of Common UGT1A8, UGT1A9, and UGT2B7 Variants with Different Capacities to Inactivate Mutagenic 4-Hydroxylated Metabolites of Estradiol and Estrone Cancer Res., January 1, 2006; 66(1): 125 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Martignoni, M. Cosentino, M. Ferrari, G. Porta, E. Mattarucchi, F. Marino, S. Lecchini, and G. Nappi Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism Neurology, December 13, 2005; 65(11): 1820 - 1822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Verlaan, J P H Drenth, K Truninger, M Koudova, H-U Schulz, M Bargetzi, B Kunzli, H Friess, M Cerny, A Kage, et al. Polymorphisms of UDP-glucuronosyltransferase 1A7 are not involved in pancreatic diseases J. Med. Genet., October 1, 2005; 42(10): e62 - e62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Butler, Y. Duguay, R. C. Millikan, R. Sinha, J.-F. Gagne, R. S. Sandler, and C. Guillemette Joint Effects between UDP-Glucuronosyltransferase 1A7 Genotype and Dietary Carcinogen Exposure on Risk of Colon Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1626 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Kuehl, J. W. Lampe, J. D. Potter, and J. Bigler GLUCURONIDATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: IDENTIFYING THE ENZYMES RESPONSIBLE IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., July 1, 2005; 33(7): 1027 - 1035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hukkanen, P. Jacob III, and N. L. Benowitz Metabolism and Disposition Kinetics of Nicotine Pharmacol. Rev., March 1, 2005; 57(1): 79 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Carlini, N. J. Meropol, J. Bever, M. L. Andria, T. Hill, P. Gold, A. Rogatko, H. Wang, and R. L. Blanchard UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan Clin. Cancer Res., February 1, 2005; 11(3): 1226 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.M.J. van der Logt, S.M. Bergevoet, H.M.J. Roelofs, Z. van Hooijdonk, R.H.M. te Morsche, T. Wobbes, J.B. de Kok, F.M. Nagengast, and W.H.M. Peters Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk Carcinogenesis, December 1, 2004; 25(12): 2407 - 2415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lepine, O. Bernard, M. Plante, B. Tetu, G. Pelletier, F. Labrie, A. Belanger, and C. Guillemette Specificity and Regioselectivity of the Conjugation of Estradiol, Estrone, and Their Catecholestrogen and Methoxyestrogen Metabolites by Human Uridine Diphospho-glucuronosyltransferases Expressed in Endometrium J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5222 - 5232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Bernard and C. Guillemette THE MAIN ROLE OF UGT1A9 IN THE HEPATIC METABOLISM OF MYCOPHENOLIC ACID AND THE EFFECTS OF NATURALLY OCCURRING VARIANTS Drug Metab. Dispos., August 1, 2004; 32(8): 775 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Paoluzzi, A. S. Singh, D. K. Price, R. Danesi, R. H. J. Mathijssen, J. Verweij, W. D. Figg, and A. Sparreboom Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN-38 J. Clin. Pharmacol., August 1, 2004; 44(8): 854 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Wells, P. I. Mackenzie, J. Roy Chowdhury, C. Guillemette, P. A. Gregory, Y. Ishii, A. J. Hansen, F. K. Kessler, P. M. Kim, N. Roy Chowdhury, et al. GLUCURONIDATION AND THE UDP-GLUCURONOSYLTRANSFERASES IN HEALTH AND DISEASE Drug Metab. Dispos., March 1, 2004; 32(3): 281 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Duguay, M. McGrath, J. Lepine, J.-F. Gagne, S. E. Hankinson, G. A. Colditz, D. J. Hunter, M. Plante, B. Tetu, A. Belanger, et al. The Functional UGT1A1 Promoter Polymorphism Decreases Endometrial Cancer Risk Cancer Res., February 1, 2004; 64(3): 1202 - 1207. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
